Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
暂无分享,去创建一个
Marilyn M. Li | T. Burns | S. Ramalingam | D. Gerber | D. Camidge | D. Weaver | P. Scaglioni | D. Morgensztern | D. Spigel | M. Keegan | R. Kelly | W. Jeong | J. Horobin | Song Zhang | Jeremey Cetnar | Louis Vaikus
[1] N. Pavlakis,et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] AMG 510 First to Inhibit "Undruggable" KRAS. , 2019, Cancer discovery.
[3] P. Zarrinkar,et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.
[4] E. Giovannetti,et al. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN , 2017, Oncotarget.
[5] P. Jänne,et al. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Morales,et al. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer , 2016, Clinical Cancer Research.
[7] Jean Mosser,et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.
[8] C. Logothetis,et al. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. , 2015, Cancer research.
[9] Suzanne F. Jones,et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors , 2015, Investigational New Drugs.
[10] F. Kaye,et al. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. , 2015, Journal of the National Cancer Institute.
[11] P. Jänne,et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer , 2015, British Journal of Cancer.
[12] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[13] D. Planchard,et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[15] Taebo Sim,et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.
[16] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[17] Jie Huang,et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. , 2013, Journal of the National Cancer Institute.
[18] D. Gerber,et al. Baseline tumour measurements predict survival in advanced non-small cell lung cancer , 2013, British Journal of Cancer.
[19] P. Jänne,et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Giaccone,et al. Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. , 2013 .
[21] M. To,et al. The genetics and biology of KRAS in lung cancer , 2013, Chinese journal of cancer.
[22] I. Wistuba,et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. , 2013, Cancer discovery.
[23] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[24] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[25] D. Camidge,et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Weinberg,et al. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. , 2012, Cancer discovery.
[27] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[28] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[29] Edward S. Kim,et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Wicha,et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. , 2009, Cancer research.
[31] Edward S. Kim,et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.
[32] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[33] V. Brunton,et al. Src and focal adhesion kinase as therapeutic targets in cancer. , 2008, Current opinion in pharmacology.
[34] D. Schlaepfer,et al. Multiple connections link FAK to cell motility and invasion. , 2004, Current opinion in genetics & development.
[35] P. Casey,et al. High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.
[36] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.